deferiprone has been researched along with Tauopathies in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (DFP) is a clinically available iron chelator, which has demonstrated potential therapeutic advantages of chelating iron in neurodegenerative disorders, and is currently in clinical trials for AD." | 1.62 | Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. ( Adlard, PA; Finkelstein, DI; Lago, L; McColl, G; Rao, SS; Shukla, JJ; Volitakis, I, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, SS | 2 |
| Portbury, SD | 1 |
| Lago, L | 2 |
| Bush, AI | 1 |
| Adlard, PA | 2 |
| Volitakis, I | 1 |
| Shukla, JJ | 1 |
| McColl, G | 1 |
| Finkelstein, DI | 1 |
2 other studies available for deferiprone and Tauopathies
| Article | Year |
|---|---|
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
Topics: Animals; Deferiprone; Disease Models, Animal; Female; Iron; Iron Chelating Agents; Male; Maze Learni | 2020 |
Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.
Topics: Aging; Animals; Deferiprone; Female; Humans; Iron Chelating Agents; Male; Maze Learning; Mice; Mice, | 2021 |